Investigational drug

An investigational drug is a compound being formally tested in clinical trials but not yet FDA-approved for that use. The label tells you a real development program exists; it does not tell you the drug works, is safe enough for routine use, or will eventually win approval. Think stage, not verdict.

What does investigational mean on a drug badge?

Investigational means researchers are testing a drug under formal clinical protocols to learn whether it is safe, effective, and useful for a specific condition. The FDA’s patient guide also calls these experimental drugs. Trial oversight is meaningful, but enrollment is not an endorsement. A study exists because the answer is still being worked out.

On Molecular Reference, the badge answers one question: has this compound entered registered human drug development? Read the evidence grade for what the studies showed. A phase number measures testing progress, not the result’s strength. Phase 3 can still disappoint. Science retains the right to ruin a launch party.

How does investigational status work at the FDA?

Investigational status at the FDA sits before marketing approval. An investigational new drug application lets a sponsor conduct human trials; approval requires a later review of evidence for a defined product and use. Until that happens, the drug does not inherit the safety, effectiveness, manufacturing, or labeling conclusions attached to an approved product. The regulatory-status guide keeps those lanes separate.

This is also different from a research-use-only label. On this site, “investigational” means formal registered human trials exist. “Research-use-only” describes material sold for laboratory work, not a clinical-development milestone. A gray-market vial does not become a trial drug because the same molecule is under study elsewhere.

What is the investigational vs approved drug difference?

The investigational vs approved drug difference is evidence plus regulatory review for a specific use. An approved drug has cleared FDA review for its labeled indication; an investigational drug is still generating or submitting that case. Being studied is evidence of organized testing, not evidence that the treatment works. That distinction matters whenever a promising mechanism outruns the results.

Retatrutide is the concrete 2026 example. ClinicalTrials.gov lists TRIUMPH-3 as a phase 3 retatrutide study that is active but no longer recruiting, with its record updated May 22, 2026. Retatrutide therefore has an investigational badge and late-stage human evidence, yet the FDA still states that retatrutide is not part of an FDA-approved drug and has not been found safe and effective for any condition. Both facts can be true at once.